PharmTech Europe News

EMA Earns EMAS Certification

February 17, 2025

The agency has received certification with the Eco-Management and Audit Scheme for its commitment to environmental sustainability.

European Drug Shortage Monitoring Platform Fully Operational

January 29, 2025

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

January 15, 2025

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

EMA Prepared for Health Technology Assessment Regulation Implementation

January 10, 2025

The HTAR, which aims to increase access to new medicines, becomes effective Jan. 12, 2025.

Protection of Personal Data in European Medicine Regulation

December 25, 2024

Revised guidelines published by EMA and HMA update the rules on identification of commercially confidential information and personal data used in marketing authorization applications.

Innovation, Collaboration, and Performance Were Highlights for EMA in 2024

December 24, 2024

Emer Cooke, executive director of EMA, is encouraged by the competitiveness of the European pharmaceutical market.

Electronic Product Information Moves Forward in Europe

December 17, 2024

A pilot program to explore creation and testing of ePIs in regulatory procedures shows positive results.

Several Orphan Drugs Among Medicines Recommended for Approval by EMA in December

December 16, 2024

EMA recommended 17 drugs for marketing authorization in December, including treatments for rare heart conditions, anemia, and liver disease.

TekniPlex Healthcare to Announce Expanded Capacity at Pharmapack Europe

December 13, 2024

The company will be showcasing its injection blow molded bottles and five-layer blown film at the packaging event in Paris on Jan. 22–23, 2025.

GSK Enters into Strategic Collaborations with Relation and Muna to Advance Drug Development

December 12, 2024

With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.